The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Abstract
CONTEXT: The alpha7 nicotinic acetylcholine receptor gene, CHRNA7, is associated with genetic transmission of schizophrenia and related cognitive and neurophysiological sensory gating deficits. Cognitive dysfunction is responsible for significant psychosocial disability in schizophrenia. Nicotine, a low-potency agonist at the alpha7 receptor, has some positive effects on neurophysiological and neurocognitive deficits associated with schizophrenia, which suggests that more effective receptor activation might meaningfully enhance cognition in schizophrenia. OBJECTIVES: To determine if 3-[(2,4-dimethoxy)benzylidene]anabaseine (DMXB-A), a natural alkaloid derivative and a partial alpha7 nicotinic cholinergic agonist, significantly improves neurocognition, and to assess, by effects on P50 auditory evoked potential inhibition, whether its neurobiological actions are consistent with activation of alpha7 nicotinic receptors. DESIGN: Randomized, double-blind crossover trial of 2 drug doses and 1 placebo. SETTING: General clinical research center. PATIENTS: Twelve persons with schizophrenia who did not smoke and were concurrently treated with antipsychotic drugs. One person was withdrawn because of a transient decrease in white blood cell count. INTERVENTION: Administration of DMXB-A. MAIN OUTCOME MEASURES: Total scale score of the Repeatable Battery for the Assessment of Neuropsychological Status and P50 inhibitory gating. RESULTS: Significant neurocognitive improvement was found on the Repeatable Battery for the Assessment of Neuropsychological Status total scale score, particularly for the lower DMXB-A dose compared with placebo. Effects were greater than those of nicotine in a similar study. Significant improvement in P50 inhibition also occurred. Patients generally tolerated the drug well. CONCLUSIONS: An alpha7 nicotinic agonist appears to have positive effects on neurocognition in persons with schizophrenia. Longer trials are needed to determine the clinical utility of this novel treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 5×
“locus of CHRNA7.(2) Polymorphisms in the gene and its nearby partial duplication are associated with diminished P50 inhibition and cognitive dysfunction.”
BackgroundMethodResultInfluentialSelf-citationNormalization of auditory physiology by cigarette smoking in schizophrenic patients
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1856 · Cited by 679
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678
Self-citationBilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
INPUT DYSFUNCTION IN SCHIZOPHRENIA.
Venables, P. H. (1964) · PubMed · Cited by 473
Leonard, S., Gault, J., Hopkins, J., Logel, J., Vianzon, R., Short, M., Drebing, C., Berger, R., Venn, D., Sirota, P., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1085 · Cited by 441
Self-citationFrazier, C. J., Rollins, Y. D., Breese, C. R., Leonard, S., Freedman, R., & Dunwiddie, T. V. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01187.1998 · Cited by 374
Self-citationGold, J. M., Queern, C., Iannone, V. N., & Buchanan, R. W. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1944 · Cited by 325
Selective α 7 -nicotinic agonists normalize inhibition of auditory response in DBA mice
Stevens, K. E., Kem, W. R., Mahnir, V. M., & Freedman, R. (1998) · Psychopharmacology · doi:10.1007/s002130050573 · Cited by 269
Self-citationKaufmann, C. A., Suarez, B., Malaspina, D., Pepple, J., Svrakic, D., Markel, P. D., Meyer, J., Zambuto, C. T., Schmitt, K., Matise, T. C., et al. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980710)81:4<282::aid-ajmg2>3.0.co;2-w · Cited by 267
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Taly, A., Corringer, P.-J., Guedin, D., Lestage, P., & Changeux, J.-P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2927 · Cited by 703
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Self-citationThe alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation
de Jonge, W. J., & Ulloa, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707264 · Cited by 629
The Hippocampal Formation in Schizophrenia
Tamminga, C. A., Stan, A. D., & Wagner, A. D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081187 · Cited by 582
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky, B. I., Calkins, M. E., Light, G. A., Olincy, A., Radant, A. D., & Swerdlow, N. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl060 · Cited by 567
Self-citationPsychiatric genetics: progress amid controversy
Burmeister, M., McInnis, M. G., & Zöllner, S. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2381 · Cited by 525
Nicotinic acetylcholine receptors: From basic science to therapeutics
Hurst, R., Rollema, H., & Bertrand, D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.012 · Cited by 522
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
Braff, D. L., Freedman, R., Schork, N. J., & Gottesman, I. I. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl049 · Cited by 455
Self-citationNicotinic ACh receptors as therapeutic targets in CNS disorders
Dineley, K. T., Pandya, A. A., & Yakel, J. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.002 · Cited by 450
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Self-citationP50 sensory gating ratios in schizophrenics and controls: A review and data analysis
Patterson, J. V., Hetrick, W. P., Boutros, N. N., Jin, Y., Sandman, C., Stern, H., Potkin, S., & Bunney, W. E. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.02.009 · Cited by 352
Neurophysiological biomarkers for drug development in schizophrenia
Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., & Hajós, M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2463 · Cited by 342
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection
Egea, J., Buendia, I., Parada, E., Navarro, E., León, R., & Lopez, M. G. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.032 · Cited by 298
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Marotta, R., Risoleo, M. C., Messina, G., Parisi, L., Carotenuto, M., Vetri, L., & Roccella, M. (2020) · Brain Sciences · doi:10.3390/brainsci10030163 · Cited by 279
“3-(2,4-Dimethoxybenzylidene)-anabaseine (DMXB-A) is a selective partial agonist for α7- nAChRs and has shown its efficacy in a randomized, double-blind crossover trial on neurocognitive improvements in subjects with schizophrenia [100].”
BackgroundThe vagal innervation of the gut and immune homeostasis
Matteoli, G., & Boeckxstaens, G. E. (2013) · Gut · doi:10.1136/gutjnl-2012-302550 · Cited by 276
Acetylcholine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders
Lester, D. B., Rogers, T. D., & Blaha, C. D. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00142.x · Cited by 259
Carbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 258
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Self-citationNeural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses
Miwa, J. M., Freedman, R., & Lester, H. A. (2011) · Neuron · doi:10.1016/j.neuron.2011.03.014 · Cited by 205
Self-citationSensory gating: A translational effort from basic to clinical science
Cromwell, H. C., Mears, R. P., Wan, L., & Boutros, N. N. (2008) · Clinical EEG and Neuroscience · doi:10.1177/155005940803900209 · Cited by 204
McNaughton, N., Kocsis, B., & Hajós, M. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee82e3 · Cited by 187
“For example, cognitive enhancing actions of a7 nAChR agonists have been observed both preclinically in various animal models (Levin et al., 2006; Wishka et al., 2006; Pichat et al., 2007) and in clinical studies (Kitagawa et al., 2003; Olincy et al., 2006).”
BackgroundGalantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling
Guidotti, A., Dong, E., Kundakovic, M., Satta, R., Grayson, D. R., & Costa, E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.010 · Cited by 130
Endophenotypes of obsessive-compulsive disorder: rationale, evidence and future potential
Chamberlain, S. R., & Menzies, L. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.36 · Cited by 123
Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace, T. L., Ballard, T. M., Pouzet, B., Riedel, W. J., & Wettstein, J. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.022 · Cited by 127
Histone modifications, DNA methylation, and Schizophrenia
Gavin, D. P., & Sharma, R. P. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.10.010 · Cited by 121
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Gamma oscillation deficits and the onset and early progression of schizophrenia
Woo, T.-U. W., Spencer, K., & McCarley, R. W. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747609 · Cited by 96
P50 gating deficit in Alzheimer dementia correlates to frontal neuropsychological function
Thomas, C., vom Berg, I., Rupp, A., Seidl, U., Schröder, J., Roesch-Ely, D., Kreisel, S. H., Mundt, C., & Weisbrod, M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.002 · Cited by 88
Konradsson‐Geuken, Å., Gash, C. R., Alexander, K., Pomerleau, F., Huettl, P., Gerhardt, G. A., & Bruno, J. P. (2009) · Synapse · doi:10.1002/syn.20693 · Cited by 71
Rezvani, A. H., Cauley, M., Sexton, H., Xiao, Y., Brown, M. L., Paige, M. A., McDowell, B. E., Kellar, K. J., & Levin, E. D. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2161-8 · Cited by 50
Barbier, A. J., Hilhorst, M., Vliet, A. V., Snyder, P., Palfreyman, M. G., Gawryl, M., Dgetluck, N., Massaro, M., Tiessen, R., Timmerman, W., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.013 · Cited by 51
Ben-Zeev, D., Brian, R. M., Aschbrenner, K. A., Jonathan, G., & Steingard, S. (2018) · Psychiatric Rehabilitation Journal · doi:10.1037/prj0000197 · Cited by 50
Cognitive Remediation in Schizophrenia
Kaneko, Y., & Keshavan, M. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.3.125 · Cited by 51
Drug tolerance: a known unknown in translational neuroscience
Bespalov, A., Müller, R., Relo, A.-L., & Hudzik, T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.008 · Cited by 50
Lee, C.-H., & Hung, S.-Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010031 · Cited by 50
Acetylcholinesterase inhibitors may improve myelin integrity
Bartzokis, G. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.020 · Cited by 41
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Self-citationSinha, N., Karche, N. P., Verma, M. K., Walunj, S. S., Nigade, P. B., Jana, G., Kurhade, S. P., Hajare, A. K., Tilekar, A. R., Jadhav, G. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01569 · Cited by 30
Bristow, L. J., Easton, A. E., Li, Y.-W., Sivarao, D. V., Lidge, R., Jones, K. M., Post-Munson, D., Daly, C., Lodge, N. J., Gallagher, L., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159996 · Cited by 30
Stoiljkovic, M., Leventhal, L., Chen, A., Chen, T., Driscoll, R., Flood, D., Hodgdon, H., Hurst, R., Nagy, D., Piser, T., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.006 · Cited by 29
Caldirola, D., Daccò, S., Grassi, M., Citterio, A., Menotti, R., Cavedini, P., Girardi, P., & Perna, G. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07985 · Cited by 27
Acheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26
Othman, A. A., Lenz, R. A., Zhang, J., Li, J., Awni, W. M., & Dutta, S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010370460 · Cited by 24
Metadata
- Authors
- Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., Stevens, J. O., Martin, L., Adler, L. E., Soti, F., Kem, W. R., & Freedman, R.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-06-01
- Volume
- 63
- Issue
- 6
- Pages
- 630
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2124533302
- Cited by
- 527
- References
- 44
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.